ArticleRheumatology and therapy2026
Serum SCUBE1 and SCUBE2 Levels in Children with Immunoglobulin A Vasculitis: An Exploratory Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionSCUBE1 and SCUBE2 are vascular-associated proteins involved in endothelial processes. Although these molecules have been investigated in several vascular and inflammatory disorders, their potential involvement in pediatric immunoglobulin A vasculitis (IgAV) has not yet been elucidated. IgAV is the most common systemic vasculitis of childhood, characterized by leukocytoclastic vasculitis and immune complex deposition, yet its biomarker profile remains incompletely understood. We explored the association of SCUBE proteins with inflammatory markers in pediatric IgAV.
methodsTwenty-six children diagnosed with IgAV according to the Ankara 2008 criteria were prospectively included. Serum SCUBE1, SCUBE2, interleukin (IL)-1, IL-6, and tumor necrosis factor alpha (TNFα) levels were measured during both the active and recovery phases of the disease. Findings were compared with age- and sex-matched healthy controls using enzyme-linked immunosorbent assay (ELISA) methods.
resultsIL-1 and IL-6 levels were significantly elevated in patients during the active phase compared with healthy controls (p = 0.006 and p = 0.01, respectively), supporting their role in acute inflammation. SCUBE1 and SCUBE2 levels did not significantly differ between active and recovery phases. However, SCUBE2 levels were significantly lower in the recovery phase than in controls (p = 0.008), suggesting potential downregulation following acute inflammation.
conclusionsOur findings indicate that SCUBE2 may be more closely related to late-stage vascular stabilization or tissue repair mechanisms rather than acute inflammatory activity in IgAV. This preliminary finding suggests that SCUBE2 may be associated with post-inflammatory processes; however, further studies are required to clarify its clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.